# Biomatter Designs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomatter-designs

- Industry: Biotechnology
- Headquarters: Lithuania
- Website: www.biomatter.ai/
- Total disclosed funding: $7.7M
- Latest round: Seed (Aug 1, 2024)
- Investors on record: 5

## About

Based in Lithuania, Biomatter Designs specializes in advanced enzyme design through its Intelligent Architecture™ platform, enabling the rapid creation of novel enzyme-based solutions for a variety of industries.Biomatter Designs, founded in 2018, focuses on enzyme design technology. The co-founders include Donatas Repecka, Laurynas Karpus, Rolandas Meškys, and Vykintas Jauniskis. Laurynas Karpus serves as the CEO. In August 2024, the company raised EUR 6.5 million in Seed funding, which is the total amount raised to date, involving investors such as Inventure, Metaplanet Holdings, Practica Capital, and Unternehmertum Venture Capital. The firm is based in Lithuania, contributing to two deals so far, with the latest deal dated August 1, 2024.Biomatter specializes in advanced enzyme design through its Intelligent Architecture™ platform, allowing precise control over protein design. This platform facilitates the creation of novel enzyme-based products and technologies, significantly advancing enzyme engineering and reducing time to market. Biomatter serves various industries, including biopharmaceuticals, industrial biotechnology, and sustainable manufacturing, providing customized solutions from concept to experimental validation and scale-up, with partnerships including Kirin Holdings and ArcticZymes Technologies. Their products mainly target European and North American markets for applications in chemical manufacturing and infant nutrition.Biomatter's revenue model is based on collaborations with companies across sectors, involving bespoke agreements for joint development of enzyme products. Their flagship offerings, such as LYNX Enzyme Optimization™, are integrated into these agreements, generating revenue through project-based transactions, which include upfront fees, milestone payments, and potential royalties on sales of developed enzyme products. In 2022, Biomatter generated revenue of EUR 438,226.50, with an EBITDA of EUR -151,155.90.In August 2024, Biomatter Designs secured EUR 6.5 million in Seed funding, co-led by new investors Inventure and Unternehmertum Venture Capital, to enhance its capabilities in producing de novo enzymes. The company plans to develop new enzyme products and expand into new markets, with a focus on addressing the needs of industries requiring innovative enzyme solutions. The funding will support the enhancement of their Intelligent Architecture™ platform, enabling them to better serve clients across Europe and North America.

## Funding rounds

- Seed, Aug 1, 2024, $7.1M — Inventure, Unternehmertum Venture Capital, Practica Capital, Metaplanet Holdings
- Seed, Jan 11, 2021, $0.6M — Practica Capital, 70ventures

## Investors

- Practica Capital (https://capitalatlas.ai/funds/practica-capital) — Seed
- 70ventures — Seed
- Inventure (https://capitalatlas.ai/funds/inventure) — Seed
- Unternehmertum Venture Capital (https://capitalatlas.ai/funds/unternehmertum-venture-capital) — Seed
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Seed